• Regulatory NewsRegulatory News

    FDA Warns of Increased Risk of Serious Pancreatitis with Allergan’s Viberzi

    Following the death of two patients without a gallbladder on Allergan’s irritable bowel drug Viberzi (eluxadoline), the US Food and Drug Administration (FDA) on Wednesday warned about the increased risk of serious pancreatitis in such patients. Viberzi is approved by FDA for use in adults for the treatment of irritable bowel syndrome with diarrhea. From May 2015, when Viberzi was first approved, through February 2017, FDA says it received 120 reports of serious cases ...